Home / Central Data Catalog / FRESH-PEF2849-EN
central

Localized psoriasis: a pharmaco-economic evaluation

France, 2009 - 2010
Reference ID
FRESH-PEF2849-en
Producer(s)
Nicholas;MOORE
Metadata
DDI/XML JSON
Study website Interactive tools
Created on
Feb 18, 2026
Last modified
Feb 18, 2026
Page views
35
  • Identification
  • Scope
  • Coverage
  • Producers and sponsors
  • Study authorization
  • Sampling
  • Survey instrument
  • Data collection
  • Study activities
  • Access policy
  • Data Access
  • Contacts

    • Identification

    Survey ID number

    FRESH-PEF2849-en
    Title

    Localized psoriasis: a pharmaco-economic evaluation
    Abbreviation or Acronym

    PSOLEMEE
    Country
    Name Country code
    France fr
    Kind of Data

    ['Clinical data','Socio-demographic data','Participant-reported health data']
    Unit of Analysis

    Individuals

    Scope

    Topics
    Topic Vocabulary
    Dermatology health theme
    Healthcare system determinants: Use of care health determinant
    Healthcare system determinants health determinant
    Keywords
    cost pharmaco-economic study Psoriasis quality of life cohort pharmacoepidemiology Department of Pharmacology Bordeaux

    Coverage

    Universe

    {"level_sex_clusion_I":[{"value":"Male","concept":{"vocab":"MeSH","vocabURI":"D008297"}},{"value":"Female","concept":{"vocab":"MeSH","vocabURI":"D005260"}}],"level_age_clusion_I":[{"value":"Young Adult (19 to 24 years)","concept":{"vocab":"MeSH","vocabURI":"D055815"}},{"value":"Adult (25 to 44 years)","concept":{"vocab":"MeSH","vocabURI":"D000328"}},{"value":"Middle Aged (45 to 64 years)","concept":{"vocab":"MeSH","vocabURI":"D008875"}},{"value":"Aged (65 to 79 years)","concept":{"vocab":"MeSH","vocabURI":"D000368"}},{"value":"Aged, 80 and over (80 years and more)","concept":{"vocab":"MeSH","vocabURI":"D000369"}}],"level_type_clusion_I":"Patients population","level_type_clusion_other":"","clusion_I":"Patient aged 18 years or above; Patient with chronic plaque psoriasis; Patient with plaques located in places difficult to treat (knees, elbows, and anterior tibia, not exceeding 5% of the body surface area); Patient able to understand or complete the study questionnaires; patient who can be followed for 6 months; patient agreeing to participate in the study.","clusion_E":""}

    Producers and sponsors

    Primary investigators
    Name
    Nicholas;MOORE
    Producers
    Name Role
    UNIVERSITE DE BORDEAUX sponsor
    Funding Agency/Sponsor
    Name
    IBSA PHARMA SAS

    Study authorization

    Agency
    Agency name
    CNIL

    Sampling

    Sample frame

    Unit Type

    ['Through organizations (health services or institutions, schools, businesses, etc.)','Through independent healthcare practitioners']
    Sampling Procedure

    ['{"concept":{"vocabURI":"Other","vocab":"CESSDA"},"value":"Other"}']

    Survey instrument

    Questionnaires

    Access on specific project only
    Methodology notes

    Observational Study

    Data collection

    Dates of Data Collection
    Start End
    2009-01-01 2010-01-01
    Mode of data collection
    • {"concept":{"vocabURI":"SelfAdministeredQuestionnaire","vocab":"CESSDA"},"value":"Self-administered questionnaire"}
    • {"concept":{"vocabURI":"Interview","vocab":"CESSDA"},"value":"Interview with the participant (including clinical)"}

    Study activities

    Study activities
    Type
    primary evaluation
    Description
    Health event/morbidity Health care consumption and services Quality of life/health perception

    Access policy

    Notes

    Ownership of study data is the subject of an agreement between the University Bordeaux Segalen and the pharmaceutical company.

    Data Access

    Availability Status

    {"value":"To be defined","extLink":[]}

    Contacts

    Contacts
    Name Email
    Nicholas;MOORE nicholas.moore@u-bordeaux.fr
    Back to Catalog